Department of Diagnostic and Interventional Radiology, Hôpital Pellegrin, 2 Place Amélie Raba-Léon, 33000, Bordeaux, France.
Bordeaux Institute of Oncology, BRIC U1312, INSERM, Université de Bordeaux, Bâtiment Bordeaux Biologie Santé, 2 Rue Dr Hoffmann Martinot, 33000, Bordeaux, France.
Eur Radiol. 2024 Mar;34(3):1567-1577. doi: 10.1007/s00330-023-10188-z. Epub 2023 Aug 31.
We investigated the efficacy of iliofemoral venous stenting in women of childbearing age treated for post-thrombotic syndrome (PTS) and assessed the influence of pregnancy on stent occlusion.
A retrospective analysis was conducted on women of childbearing age who underwent endovascular stenting for PTS due to chronic iliocava occlusion across 15 centers from 2009 to 2020. The study assessed pregnancy rates, primary patency rates, secondary patency rates, and clinical efficacy using the Villalta score for PTS severity and the Chronic Venous Disease Quality of Life Questionnaire - version 20 (CIVIQ-20), 6-12 months after the procedure. The impact of pregnancy on stent occlusion was analyzed using classical and multi-state survival analyses. Prophylactic low-molecular-weight heparin or fondaparinux was administered to patients during pregnancy until 6 weeks post-partum.
In total, 211 women with PTS underwent endovascular stenting, with a median age of 31 years (range: 16-42). Following recanalization, significant improvements were observed in the Villalta score (p < 0.0001) and the CIVIQ-20 score (p < 0.0001). Thirty-seven (17.6%) women became pregnant and 49 (23.2%) experienced stent occlusions. The 1-year and 5-year occlusion-free survival probabilities were 80.6% (95% confidence interval [CI]: 75.1-86.4%) and 66.6% (95% CI: 57.4-77.4%), respectively. There was no significant association between pregnancy and stent occlusion-free survival (hazard ratio = 1.00 [95% CI: 0.11-8.92], p = 0.9930).
Iliofemoral venous stenting in women of childbearing age was an effective treatment for post-thrombotic syndrome, and it did not increase the risk for stent occlusion during pregnancy when accompanied by appropriate anticoagulation.
This study demonstrates that pregnancy following iliofemoral venous stenting for post-thrombotic syndrome does not elevate the risk for stent occlusion.
• The severity of post-thrombotic syndrome and the quality of life, as measured using the Villalta score and Chronic Venous Disease Quality of Life Questionnaire - version 20, respectively, showed significant improvements 6-12 months after iliofemoral venous stenting. • The occurrence of pregnancy after recanalization in women of childbearing age did not lead to a significant increase in the risk for stent occlusion.
研究髂股静脉支架置入术治疗血栓后综合征(PTS)育龄妇女的疗效,并评估妊娠对支架闭塞的影响。
对 2009 年至 2020 年间 15 个中心因慢性髂腔静脉闭塞而行腔内支架置入术的育龄期妇女进行回顾性分析。采用 Villalta 评分评估 PTS 严重程度和慢性静脉疾病生活质量问卷-第 20 版(CIVIQ-20)评估妊娠率、一期通畅率、二期通畅率和临床疗效,术后 6-12 个月。采用经典和多状态生存分析评估妊娠对支架闭塞的影响。妊娠期间给予患者低分子肝素或磺达肝癸钠预防治疗,直至产后 6 周。
共 211 例 PTS 患者行血管内支架置入术,中位年龄 31 岁(范围:16-42 岁)。再通后,Villalta 评分(p<0.0001)和 CIVIQ-20 评分(p<0.0001)均显著改善。37 例(17.6%)妇女妊娠,49 例(23.2%)支架闭塞。1 年和 5 年无闭塞生存率分别为 80.6%(95%可信区间[CI]:75.1-86.4%)和 66.6%(95% CI:57.4-77.4%)。妊娠与支架无闭塞生存率无显著相关性(风险比=1.00[95%CI:0.11-8.92],p=0.9930)。
髂股静脉支架置入术治疗育龄期妇女血栓后综合征是一种有效的治疗方法,在伴有适当抗凝治疗的情况下,妊娠不会增加支架闭塞的风险。
本研究表明,髂股静脉支架置入术后妊娠不会增加支架闭塞的风险。
•髂股静脉支架置入术后 6-12 个月,采用 Villalta 评分和慢性静脉疾病生活质量问卷-第 20 版分别评估 PTS 严重程度和生活质量,均显示显著改善。•在生育期妇女再通后妊娠并不会显著增加支架闭塞的风险。